UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040441
Receipt number R000046141
Scientific Title The investigation for the usefulness of carnitine medication in patients with decompensated liver cirrhosis
Date of disclosure of the study information 2020/06/01
Last modified on 2020/11/16 21:10:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The investigation for the usefulness of carnitine medication in patients with decompensated liver cirrhosis

Acronym

The usefulness of carnitine medication in patients with decompensated liver cirrhosis

Scientific Title

The investigation for the usefulness of carnitine medication in patients with decompensated liver cirrhosis

Scientific Title:Acronym

The usefulness of carnitine medication in patients with decompensated liver cirrhosis

Region

Japan


Condition

Condition

decompensated liver cirrhosis

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Efficacy

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

the improvement rate of Child-Pugh score after 12weeks from medication start

Key secondary outcomes

the change of grasping power, muscle mass, serum ammonia, neuropsychological test


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -no one is blinded

Control

No treatment

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

L-carnitine 1500mg/day medication for 12 weeks

Interventions/Control_2

non administration group

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The decompensated liver cirrhosis patients with Child-Pugh score over 7 points

Key exclusion criteria

1)The patient who has already taken carnitine
2)The pregnant woman
3)The breast-feeding women
4)The patient who received other study medicine or the clinical experimental medicine within three months before dosage start of the study

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Akinobu
Middle name
Last name Takaki

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Division name

Department of Gastroenterology and Hepatology

Zip code

7008558

Address

2-5-1 Sikatacho, Kitaku, Okayama city, Okayama, japan

TEL

086-235-7219

Email

akitaka@md.okayama-u.ac.jp


Public contact

Name of contact person

1st name Takuya
Middle name
Last name Adachi

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Division name

Department of Gastroenterology and Hepatology

Zip code

7008558

Address

2-5-1 Sikatacho, Kitaku, Okayama city, Okayama, japan

TEL

086-235-7219

Homepage URL


Email

adataku719@yahoo.co.jp


Sponsor or person

Institute

Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Institute

Department

Personal name



Funding Source

Organization

epartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Address

2-5-1 Sikatacho, Kitaku, Okayama city, Okayama, japan

Tel

086-235-6610

Email

chiken@okayama-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

0

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2020 Year 07 Month 28 Day

Date of IRB

2020 Year 07 Month 28 Day

Anticipated trial start date

2020 Year 08 Month 01 Day

Last follow-up date

2023 Year 07 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 05 Month 18 Day

Last modified on

2020 Year 11 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046141


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name